Fate therapeutics inc
FATE 投資分析
看多重點:
- 價值≥4
- 股利≥2
分析結論
價值面獲得最高評分,但股利評分未超過2分,若公司開始配息,可能會有更優異的投資結果
FATE 近期報酬表現
-
Fate therapeutics inc
1.20%
同產業平均
0.11%
S&P500
與 FATE 同產業的標的表現
股票代碼 | 公司名稱 | 價值 | 趨勢 | 波段 | 籌碼 | 股利 | 加入追蹤 |
---|---|---|---|---|---|---|---|
VCYT | Veracyte inc | 3 分 | 1 分 | 2 分 | 2 分 | 1 分 | |
TWST | Twist bioscience corp | 3 分 | 5 分 | 4 分 | 2 分 | 1 分 | |
BEAM | Beam therapeutics inc | 2 分 | 5 分 | 3 分 | 3 分 | 1 分 | |
SANA | Sana biotechnology inc | 2 分 | 5 分 | 3 分 | 2 分 | 1 分 | |
GH | Guardant health inc | 3 分 | 1 分 | 2 分 | 3 分 | 1 分 |
- VCYT Veracyte inc價值 3 分趨勢 1 分波段 2 分籌碼 2 分股利 1 分查看更多
FATE 公司資訊
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders. Its proprietary induced pluripotent stem cells (iPSC) product platform combines multiplexed-engineering of human iPSCs with single-cell selection to create clonal master iPSC lines. The Company's platform is designed to overcome numerous limitations associated with the manufacture of cell therapies using patient- or donor-sourced cells. Utilizing its proprietary iPSC product platform, it is advancing off-the-shelf, multiplexed-engineered natural killer (NK) cell and T-cell product candidates which are selectively designed, incorporate novel synthetic controls of cell function. Its pipeline of iPSC-derived, chimeric antigen receptor (CAR)-targeted NK cell and T-cell product candidates include FT819, FT522, FT576, FT825, FT819, FT522, and others.